Background and Aims: Reactive testing has emerged as the new standard of care for managing loss of response to infliximab in inflammatory bowel disease [IBD]. Recent data suggest that proactive infliximab monitoring is associated with better therapeutic outcomes in IBD. Nevertheless, there are no data regarding the clinical utility of proactive infliximab monitoring after first reactive testing. We aimed to evaluate long-term outcomes of proactive infliximab monitoring following reactive testing compared with reactive testing alone in patients with IBD. Conclusions: This study showed that proactive infliximab monitoring following reactive testing was associated with greater drug persistence and fewer IBD-related hospitalizations than reactive testing alone.
Introduction
Anti-TNF drugs are effective for the treatment of moderate-to-severe inflammatory bowel disease [IBD]: Crohn's disease [CD] and ulcerative colitis [UC] . 1, 2 Nevertheless, up to half of patients lose response over time or develop a serious adverse event [SAE] , such as a serious infusion reaction [SIR] , necessitating drug cessation. 3 Therapeutic drug monitoring [TDM] , defined as the evaluation of drug concentration and anti-drug antibodies, has rationalized the management of secondary loss of response [SLR] of anti-TNF therapy and is more cost-effective when compared with empiric dose escalation. [4] [5] [6] [7] [8] [9] [10] Moreover, reactive TDM for optimizing infliximab therapy is associated with better endoscopic outcomes than clinical decision-making alone. 11 Recent studies have demonstrated that proactive TDM with drug titration to a target trough concentration is associated with better clinical outcomes when compared with standard of care or reactive TDM. [12] [13] [14] Nevertheless, there are no data regarding the clinical utility of initiating proactive infliximab monitoring after having performed reactive testing in IBD patients with SLR.
Thus, the aim of this study was to evaluate long-term outcomes of proactive infliximab monitoring after first reactive testing compared with reactive testing alone in patients with IBD. The investigated outcomes of interest were treatment failure and IBD-related surgery and hospitalization.
Materials and Methods

Study design and population
This was a retrospective multicenter cohort study. Consecutive IBD patients on infliximab maintenance therapy who underwent a first reactive testing in the period between September 2006 and January 2015 were eligible for the study. Exclusion criteria were total colectomy with an ileal pouch-anal anastomosis or permanent ostomy prior to infliximab TDM, no follow-up visit after first reactive TDM, a long [≥4 months] drug holiday during infliximab maintenance therapy and treatment failure within 6 months following first reactive testing. The patients were divided into two groups. Group A consisted of patients undergoing proactive infliximab monitoring with the aim of prospectively titrating infliximab, typically to a target trough concentration of 5-10 mg/mL, after reactive testing had been performed for either presumed loss of response or an infusion reaction, while Group B consisted of patients undergoing reactive testing alone, currently considered as standard of care. Patients were followed through December 2015. Therapeutic decisions were made at each physician's discretion and were reflective of real-life clinical practice. Demographic and clinical characteristics of and outcomes for the patients were acquired from their electronic medical records. The study was approved by the Institutional Review Boards of the Beth Israel Deaconess Medical Center [BIDMC], Harvard Medical School, Boston, Massachusetts and the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Definitions
Treatment failure was defined as infliximab discontinuation for loss of response or SAE. Inflammatory bowel disease-related surgery was defined as any intestinal or perianal surgical procedure performed for underlying IBD.
14 Inflammatory bowel disease-related hospitalization was defined as any hospitalization with IBD as the primary diagnosis, not associated with drug effects or other conditions, as previously described.
14 An SIR was defined as any acute or delayed infusion reaction necessitating infliximab discontinuation. The study observation time for IBD-related surgery and hospitalization was set from start of infliximab TDM until treatment failure or the end of follow-up.
Infliximab trough concentrations and antibodies to infliximab
Serum infliximab concentrations and antibodies to infliximab [ATIs] were measured by Prometheus Laboratories [San Diego, CA]. The study period overlapped with the use of two methods of TDM: a drug-sensitive in-house-developed enzyme-linked immunosorbent assay [ELISA] until July 2012, followed by the drug-tolerant homogeneous mobility shift assay [HMSA] . 15 Infliximab concentrations of <1 and 1.4 µg/mL and ATIs < 3.1 U/mL and 1.7 µg/mL equivalents were considered as undetectable for the HMSA and ELISA, respectively. Figure 3A ] and UC [ Figure 3B ]. This was also the case for patients with CD and a previous ileocolonic resection [Supplementary Figure 1A] or perianal fistulizing CD [Supplementary Figure 1B] . The first and third year cumulative probability of treatment failure in Group A was 0% and 3.4% (standard error [SE] 
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Discussion
Reactive TDM has emerged as the new standard of care for optimizing anti-TNF therapy in IBD because it can efficiently treat SLR and is more cost-effective when compared with empiric symptoms-based dose escalation. 16 However, recent studies suggest that proactive TDM is also associated with more favorable therapeutic outcomes, even compared with reactive TDM. [12] [13] [14] To our knowledge, this is the first study to demonstrate the clinical utility of proactive infliximab monitoring [dosing to a therapeutic window of >5 μg/ml] following reactive testing in IBD. We demonstrated that this therapeutic strategy of continued optimization was associated with greater drug persistence and fewer IBD-related hospitalizations compared with reactive testing alone, which is currently the standard of care.
A single-center, retrospective study by our group was the first to demonstrate the long-term benefit in terms of greater drug persistence of proactive TDM of infliximab with the goal of dosing the drug to a therapeutic window of 5-10 μg/mL compared with blind treatment optimization or reactive TDM. 13 The landmark TAXIT [Trough level Adapted infliXImab Treatment] randomized controlled trial showed that there was less need for rescue therapy and were fewer undetectable infliximab trough concentrations in patients at start of therapeutic drug monitoring. IBD: inflammatory bowel disease; CD: Crohn's disease; UC: ulcerative colitis; CI: confidence interval; IFX: infliximab; IMM: immunomodulator; TNF: tumor necrosis factor; ATI: antibodies to infliximab; IQR: interquartile range; HMSA: homogeneous mobility shift assay; w: week; IR: infusion reaction; SLR: secondary loss of response; TDM: therapeutic drug monitoring.
undergoing proactive TDM-based optimization of infliximab compared with in clinically dosed patients. 12 Additionally, dose escalation in patients with infliximab trough concentrations <3 μg/mL at screening resulted in a higher proportion of CD patients in remission, with a decrease in C-reactive protein when compared with the level pre-optimization. 12 Recently, in a large multicenter retrospective cohort study, we demonstrated that proactive TDM improved objective therapeutic outcomes, such as greater drug durability, lower risk of ATIs or SIRs and less need for IBD-related surgery or hospitalization, when compared with reactive TDM.
14 The latter, along with the application of a de-escalation therapeutic strategy, in patients with supra-therapeutic drug concentrations guided by proactive TDM can potentially decrease the cost of therapy. [12] [13] [14] In the TAXIT trial, 27% of patients underwent dose de-escalation without negative impact on remission rates. 12 In the same line, in our study 8/33 [24%] patients undergoing proactive TDM following reactive testing de-escalated infliximab therapy during the study period.
Additionally, we identified a diagnosis of UC, lower infliximab concentration at start of TDM, and male gender as associated with treatment failure. The first two variables likely characterize patients with a higher inflammatory burden and consequently a higher drug clearance and were also found to be associated with treatment failure when undergoing either proactive or reactive TDM of infliximab in a previous study.
14 Regarding the latter variable, pharmacokinetic studies have shown that men may have a higher drug clearance than women, 17 and male sex was identified as a risk factor for relapse following discontinuation of infliximab in patients with CD with stable clinical remission. 18 The limitations of this study are its retrospective nature and the potential for residual/selection bias. However, confounding factors that could influence the outcomes are likely limited in this study as all patients initially underwent reactive testing, and the two groups were similar regarding the patients' baseline and clinical characteristics. Moreover, to ensure population homogeneity and diminish potential differences in disease activity and inability to optimize infliximab as potential confounding factors, only patients without early treatment failure who were still on drug for at least 6 months after the first reactive testing were included in the study. An additional limitation of this study could be that two different assays for TDM were used based on the evolution of laboratory technology over time.
In conclusion, this study, performed in two large tertiary IBD centers, demonstrates that proactive infliximab monitoring following reactive testing can prevent treatment failure and IBD-related hospitalization and may be a valuable therapeutic option for improving the management of IBD patients treated with anti-TNF therapy who experience a SLR. Though larger prospective studies are certainly warranted, physicians currently performing reactive testing should consider incorporating future proactive monitoring for the same patients. 
Conflict of Interest
BPV: receives research support from Takeda and Genentech and has received compensation from Janssen and AbbVie for speaking and advisory boards. ASC: received consultancy fees from AbbVie, Janssen, Takeda, Ferring, Samsung, Miraca, AMAG and Pfizer; MTO: received consultancy fees from Janssen, AbbVie, UCB, Takeda, Pfizer, Merck and Lycera, and received research grant support from UCB; the remaining authors disclose no conflicts of interest.
Author Contributions
KP: study concept and design, data acquisition, analysis and interpretation, statistical analysis and manuscript writing; RKV, BPV: data acquisition and manuscript critical revision; ASC, MO: study concept and design, data analysis and interpretation and manuscript critical revision. All the authors approved the final draft. 
